We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Senate Judiciary Committee members and generics makers in June both sung the praises of a bill aimed at preventing branded drugmakers from restricting access to their products. Read More
The U.S. Supreme Court has paved the way for the possibility of drugmakers collecting enhanced damages in patent cases, striking down an appellate standard in a unanimous 8-0 decision. Read More
AstraZeneca’s lawsuit against the FDA over the exclusivity of one of its drugs is a “transparent” effort to stifle generic competition for the blockbuster anti-cholesterol drug Crestor, the FDA said in its response to the suit. Read More
Pfizer has pledged to communicate all the risks associated with opioids in future ads under an unusual accord it reached with the city of Chicago. Read More
The UK’s National Institute for Health and Care Excellence declined to recommend Bristol-Myers Squibb’s Opdivo for reimbursement in the treatment of advanced renal cell carcinoma. Read More
Horizon Therapeutics has filed suit against Par Pharmaceutical, alleging infringement of three patents for its urea cycle disorders drug Ravicti. Read More
Medical products companies spent $7.52 billion on physicians and teaching hospitals in 2015, roughly in line with 2014 results, according to the Centers for Medicare & Medicaid Services. Read More